Bone Marrow Study Analyzes Risk for Early Relapse of Prostate Cancer

by: cancercompass

Researchers trying to identify patients at high risk for early relapse of prostate cancer found that when certain bone marrow cells are present prior to surgery, it may indicate these patients need adjuvant therapy.

German researchers genetically analyzed disseminated tumor cells in bone marrow at various stages of prostate cancer over a 10 year period. According to the study published online recently in the Journal of Clinical Oncology, the purpose of the research was to understand the dynamics of systemic disease and identify patients at high risk for early relapse of prostate cancer.

Investigators analyzed 900 bone marrow aspirates from 384 patients. They found that cytokeratin-positive cells that were present before surgery were the strongest independent risk factor for metastasis within 48 months. When these cells were detected and consistently present in bone marrow for 6 months to 10 years after radical prostatectomy, no influences on disease outcome were found.

Study authors concluded that patients with cytokeratin-positive cells in their bone marrow prior to surgery may benefit from adjuvant therapies.

Join the discussion at our Prostate Cancer Message Board to chat with survivors, caregivers and current patients about relapse, treatment options and many other topics.